Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mankind PharmaBOM:543904 -2.10%90 Gross Margin % is 72.16% as of Mar. 2026, which is 6% above its 10-year median of 68.26. GuruFocus rates BOM:543904 with a GF Score™ of 90/100 and a GF Value™ of ₹2,934.91 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 942 Drug Manufacturers companies, Mankind Pharma ranks better than 83.97% on this metric.
The historical rank and industry rank for Mankind Pharma's Gross Margin % or its related term are showing as below:
BOM:543904'
s Gross Margin % Range Over the Past 10 Years
Min: 66.14 Med: 68.26 Max: 71.62
Current: 71.62
During the past 7 years, the highestGross Margin % of Mankind Pharma was 71.62%. The lowest was 66.14%. And the median was 68.26%.
BOM:543904's Gross Margin % is ranked better than 83.97% of 942
companies
in the Drug Manufacturers industry
Industry Median: 48.54
vs BOM:543904: 71.62
Mankind Pharma had a gross margin of 72.16% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Mankind Pharma was 0.50% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Mankind Pharma had a gross margin of 72.16% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Mankind Pharma Gross Margin % Related Terms
Mankind Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for Mankind Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543904 vs ZTS, UTHR: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mankind Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mankind Pharma Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mankind Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Mankind Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Mankind Pharma (BOM:543904) has a Gross Margin % of 72.16% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Mankind Pharma and its competitors. This is near median its historical median of 68.26. Over the past decade, Mankind Pharma's Gross Margin % has ranged from 66.14 to 71.62. According to the industry distribution chart, Mankind Pharma ranks #151 out of 942 companies in the Drug Manufacturers industry, placing it in the top 16%.
Is Mankind Pharma's Gross Margin % too high?
Mankind Pharma's current Gross Margin % of 72.16% is near median its 10-year median of 68.26. Over the past 10 years, this metric has ranged from a low of 66.14 to a high of 71.62. The Drug Manufacturers industry median Gross Margin % is 48.54. Mankind Pharma's value of 72.16% is 48.7% above this industry median. Based on the distribution chart, Mankind Pharma ranks #151 out of 942 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Mankind Pharma has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mankind Pharma's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mankind Pharma ranks #151 out of 942 companies for Gross Margin %. This places Mankind Pharma in the top 16% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.54. Mankind Pharma's value of 72.16% is 48.7% above this benchmark. Historically, Mankind Pharma's own Gross Margin % has ranged from 66.14 to 71.62 over the past decade. While the company's 10-year median is 68.26 vs. the industry median of 48.54, Mankind Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mankind Pharma's current Gross Margin % of 72.16% is 48.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Mankind Pharma and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mankind Pharma's current Gross Margin % is 72.16%, which is near median its own 10-year median of 68.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mankind Pharma stock overvalued right now?
Based on GuruFocus' analysis, Mankind Pharma (BOM:543904) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,934.91, compared to a current price of ₹2,491.45 — trading 15.1% below its estimated fair value. The current Gross Margin % is 72.16%, which is near median its 10-year median of 68.26 and 48.7% above the Drug Manufacturers industry median of 48.54. Mankind Pharma's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Mankind Pharma (BOM:543904), the current Gross Margin % is 72.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mankind Pharma (BOM:543904) Overvalued in 2026?
Based on GuruFocus' analysis, Mankind Pharma stock appears to be undervalued.
The current stock price of ₹2,491.45 is trading 15.1% below its estimated GF Value™ of ₹2,934.91.
GuruFocus considers Mankind Pharma to be Modestly Undervalued.
Key valuation signals for BOM:543904:
Gross Margin %: 72.16% (near median its 10-year median of 68.26)
GF Value™: ₹2,934.91 vs. price of ₹2,491.45 (15.1% below fair value)
Industry Position: 48.7% above the Drug Manufacturers median (#151 of 942)
No single metric tells the full story. See the BOM:543904 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mankind Pharma Ltd is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It operates at the intersection of Indian pharmaceutical formulations and consumer healthcare sectors providing products at affordable prices and has an established track record of building and scaling brands in-house. The company's brands include Manforce, Prega News, Gas-O-Fast, AcneStar and HealthOK. Geographically, the company derives a majority of its revenue from the sale of pharmaceutical products in India and the rest from its customers located outside India.
90GF Score
Get the complete analysis for BOM:543904
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543904 has been successfully added to your 
